Výsledky vyhledávání - Vikas Kundra
- Zobrazuji výsledky 1 - 20 z 29
- Přejít na další stránku
-
1
Diffusion weighted imaging in prostate cancer Autor Cher Heng Tan, Jihong Wang, Vikas Kundra
Vydáno 2010Revisão -
2
-
3
-
4
-
5
Stress-inducible, Murine Protein mSTI1 Autor Michael Lässle, Gregory L. Blatch, Vikas Kundra, Toshiro Takatori, Bruce R. Zetter
Vydáno 1997Artigo -
6
Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction... Autor Baharak Bahmani, Yadir Guerrero, Danielle Bacon, Vikas Kundra, Valentine I. Vullev, Bahman Anvari
Vydáno 2014Artigo -
7
-
8
-
9
-
10
-
11
-
12
-
13
Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts Autor Edmond J. Auzenne, Sukhen C. Ghosh, Mojgan Khodadadian, Belinda Rivera, David Farquhar, Roger E. Price, Murali K. Ravoori, Vikas Kundra, Ralph S. Freedman, Jim Klostergaard
Vydáno 2007Artigo -
14
Whole-body MRI in pediatric patients with cancer Autor Marcos Duarte Guimarães, Julia Noschang, Sara Reis Teixeira, Marcel Koenigkam Santos, Henrique Manoel Lederman, Vivian Siqueira Tostes, Vikas Kundra, Alex Dias de Oliveira, Bruno Hochhegger, Edson Marchiori
Vydáno 2017Revisão -
15
PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway Autor Yong Pan, Patrea R. Rhea, Lin Tan, Carrie Cartwright, Ho-Jeong Lee, Murali K. Ravoori, Crandell Addington, Mihai Gagea, Vikas Kundra, Sun-Jin Kim, Robert A. Newman, Peiying Yang
Vydáno 2014Artigo -
16
A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity Autor Joseph R. Garlich, Pradip De, Nandini Dey, Jing Su, Xiaodong Peng, Antoinette Miller, Ravoori Murali, Yiling Lu, Gordon B. Mills, Vikas Kundra, H-K. Shu, Qiong Peng, Donald L. Durden
Vydáno 2008Artigo -
17
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages Autor Barbara Visentin, John A. Vekich, Bradley J. Sibbald, Amy L. Cavalli, Kelli Moreno, Rosalía Matteo, William Garland, Yiling Lu, Shuangxing Yu, Hassan Hall, Vikas Kundra, Gordon B. Mills, Roger A. Sabbadini
Vydáno 2006Artigo -
18
Pharmacodynamic Markers of Perifosine Efficacy Autor Bryan T. Hennessy, Yiling Lu, Enrique Poradosu, Qianghua Yu, Shuangxing Yu, Hassan Hall, Mark Carey, Murali K. Ravoori, Ana M. González-Angulo, Robert Birch, I. Craig Henderson, Vikas Kundra, Gordon B. Mills
Vydáno 2007Artigo -
19
Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer Autor Robert L. Coleman, Linda Duska, Pedro T. Ramírez, John V. Heymach, Aparna A. Kamat, Susan C. Modesitt, Kathleen M. Schmeler, Revathy B. Iyer, Michael Garcia, Debbie Miller, Edward F. Jackson, Chaan S. Ng, Vikas Kundra, Robert B. Jaffe, Anil K. Sood
Vydáno 2011Artigo -
20
Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma Autor Tae Jin Kim, Murali K. Ravoori, Charles N. Landen, Aparna A. Kamat, Liz Y. Han, Chunhua Lü, Yvonne G. Lin, William M. Merritt, Nicholas Jennings, Whitney A. Spannuth, Robert R. Langley, David M. Gershenson, Robert L. Coleman, Vikas Kundra, Anil K. Sood
Vydáno 2007Artigo
Vyhledávací nástroje:
Související témata
Medicine
Cancer
Internal medicine
Biology
Cancer research
Biochemistry
Cell biology
Pharmacology
Prostate cancer
Radiology
Chemistry
Chemotherapy
Magnetic resonance imaging
Pathology
Prostate
Angiogenesis
Apoptosis
Biotechnology
In vivo
Oncology
Physics
Receptor
Endocrinology
Gene
Genetics
Metastasis
Nuclear medicine
Ovarian cancer
PI3K/AKT/mTOR pathway
Pharmacokinetics